Key facts
- Response Pharmaceuticals’s last known valuation is $30.0M (Nov 2025).
- It has raised $16.9M across 2 recorded rounds; the latest was Early Stage VC ($8.0M) in Feb 2022.
- Notable investors include Evolution VC Partners, CrossWork, Collage Venture Partners, K2X, Momentum Biotech — 6 tracked in total.
- Response Pharmaceuticals has filed 3 Form Ds with the SEC since 2022, most recently Jun 2024 ($3.9M sold to 51 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Response Pharmaceuticals
Funding rounds
2 roundsAbout Response Pharmaceuticals
Developer an intestinal microsomal triglyceride transfer protein inhibitor designed to treat the metabolic side effects of antipsychotic drugs. The company develops treatments for post-prandial triglyceride levels, body weight, and other cardiometabolic risk factors in individuals discontinuing semaglutide or tirzepatide, enabling patients to recover from mental illness and combat weight gain and metabolic dysregulation.
- Sector
- Healthcare
- HQ
- Falls Church, VA, United States
- Founded
- 2021
- Employees
- 10
- Website
- responsepharmaceuticals.com/
- Ownership
- Privately Held (backing)
Response Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Response Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Response Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.